Bioregenx (BRGX) Common Equity (2021 - 2026)

Bioregenx has reported Common Equity for 6 years, with the latest figure at -$4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 27.38% year-over-year to -$4.5 million; the trailing twelve-month figure through Mar 2026 stood at -$4.5 million (down 27.38% YoY), and the FY2025 full-year result was -$4.5 million, down 34.27% from the prior year.
• Common Equity for Q1 2026 stood at -$4.5 million, roughly flat from -$4.5 million in the prior quarter.
• The five-year high for Common Equity was $15.1 million in Q1 2024, with the low at -$4.5 million in Q4 2025.
• Average Common Equity over 5 years is $391273.8, with a median of -$2.5 million recorded in 2022.
• Year-over-year, Common Equity tumbled 2901.09% in 2022 and surged 724.59% in 2024.
• Tracing BRGX's Common Equity over 5 years: stood at -$2.5 million in 2022, then rose by 18.06% to -$2.1 million in 2023, then slumped by 63.14% to -$3.4 million in 2024, then slumped by 34.27% to -$4.5 million in 2025, then gained by 0.09% to -$4.5 million in 2026.
• The last three Common Equity figures came in at -$4.5 million (Q1 2026), -$4.5 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.

Peer Comparison